Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

SUMMIT

Financiado

SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innov...

SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can nei... ver más

31/10/2015

BII GMBH

35M€

Presupuesto del proyecto: 35M€

Líder del proyecto

BOEHRINGER INGELHEIM INTERNATIONALGMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 24 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2015-10-31

0% 100%

24 Participantes

BII GMBH

Lider

Pfizer RD UK Limited

N.D. | Participante

UNEXE

N.D. | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

Proyectos interesantes

FJC2019-039082-I Relación de la diabetes tipo II con complicaciones microvasc... 50K€ Cerrado

CPP2021-009139 Concentrador Universal Asistido por Tecnología de Recomendac... 763K€ Cerrado

DIRECT DIabetes REsearCh on patient sTratification 46M€ Cerrado

DEP2014-52930-R INTERACCIONES ENTRE EL ENTRENAMIENTO FISICO Y LA MEDICACION... 121K€ Cerrado

BFU2011-24679 DESCIFRANDO LA RESPUESTA INTEGRAL CAPAZ DE RESTITUIR LA NORM... 115K€ Cerrado

FJCI-2017-31716 Enfermedades metabólicas (Diabetes y complicaciones clínicas... 50K€ Cerrado

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 71 meses Fecha Inicio: 2009-11-01
Fecha Fin: 2015-10-31

Líder del proyecto

BOEHRINGER INGELHEIM INTERNATIONALGMBH

TRL 4-5

Presupuesto del proyecto 35M€

Descripción del proyecto Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as well as microvascular disorders leading to damage of the small blood vessels of the kidney (nephropathy), eye(retinopathy) and peripheral nerves (neuropathy). These complications impose an immense burden on the quality of life of the patients and account for more than 10% of health care costs in Europe. Therefore, novel means to prevent these devastating diabetic complications are needed. An important mean in this undertaking would be to develop tools which would make development of novel drugs for prevention of complications more feasible. The SUMMIT consortium brings together European key leaders in the field of diabetes research; scientists with a deep insight into genetics, biomarker discovery, development of novel imaging assays for assessing progression of complications, novel animal models for chronic diabetic complications, in silico models to predict development of complications and response to novel treatments. Given the track record of this unique group of scientists, it can be anticipated that they will not only during the 6-year period discover novel surrogate markers for vascular complications in diabetes, but also validate them in large representative cohorts aiming at prevention of the devastating complications.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores